Mt. Arlington and Princeton Clinical Research Firms Form Alliance
Exodon LLC and Primera Analytical Solutions Corp., New Jersey-based clinical research firms headquartered in Mt. Arlington and Princeton, respectively, have entered into a non-exclusive strategic alliance agreement.
Exodon offers beginning-to-end early drug, biologic and nutraceutical development services from its clinical research units in the US, India, the Philippines, and Argentina. Exodon’s early drug and nutraceutical development includes multinational regulatory filings, PK/PD, BA/BE, and Phase I - IIb clinical trials. Late phase development include site selection and patient recruitment and study management for clinical trials at its SMO and TMO sites.
Primera specializes in providing bioanalytical, analytical, formulation and clinical trial analysis services for the pharmaceutical, biotechnology, agrochemical, cosmetic, and dietary supplement industries. Specific services includemethod feasibility, development, validation, method transfer, and sample analysis.
“This new business relationship will enable Exodon and Primera to jointly offer arange of services that would not be possible individually,” said Gerald Tramontano, Ph.D., Vice President, Clinical Research Operations at Exodon.
“Together, it will also allow us to offer better pricing options to our early pharmaceutical and nutraceutical clients given laboratory costs eat up a significant amount of the study budget for these types of trials,” added Paul Ernest de Leon, Director of Business Development for Exodon’s Product R&D department.
For example, this will allow Exodon to conduct such study requirements as method development, chemical validation and stability tests, and will provide Primera with applicable clinic-related assistance and facility for its research studies.
Exodon's mission is to transform research participation into an everyday connection for patients, doctors, and clients.
Primera partners with its clients in a variety of ways. The company provides customized analysis for individual studies, functions as the virtual QC department forstability assessment and product release, and performs strategic consulting in clinical trial feasibility and design.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
